Drug Profile
Hepatocyte cell therapy (Heparesc) - Cellaion
Alternative Names: Heparesc; HHLivC; Human heterologous liver cells for infusionLatest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Cytonet
- Developer Cellaion; Cytonet; Promethera Biosciences
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Inborn urea cycle disorders
Highest Development Phases
- Preregistration Inborn urea cycle disorders
- Phase II/III Liver failure
Most Recent Events
- 29 Aug 2018 Hepatocyte cell therapy (Heparesc) - Promethera Biosciences is available for licensing in Canada as of 16 Jan 2020. www.promethera.com
- 05 Oct 2017 Promethera Biosciences and Shibuya enter into collaboration to develop manufacturing platform for stem cell therapies for treatment of liver disorders
- 03 Jul 2017 Preregistration for Inborn urea cycle disorders (In children, In infants, In neonates) in Canada prior to July 2017 (IV)